This enhanced hepatic presence is represented in the blood-stream, as soluble CD36 (sCD36) was found to be increased in biopsy-staged NAFLD patients, compared to healthy controls, and as the circulating levels were even correlated with the histological grade of steatosis (123). The gene discussed is CD36; the disease is metabolic dysfunction-associated steatotic liver disease.